BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 3159522)

  • 1. Prevention of immune precipitation by purified components of the alternative pathway.
    Naama JK; Holme E; Hamilton E; Whaley K
    Clin Exp Immunol; 1985 Apr; 60(1):169-77. PubMed ID: 3159522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of immune precipitation by purified classical pathway complement components.
    Naama JK; Hamilton AO; Yeung-Laiwah AC; Whaley K
    Clin Exp Immunol; 1984 Nov; 58(2):486-92. PubMed ID: 6333948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of immune precipitation by complement.
    Hong K; Takata Y; Sayama K; Kozono H; Takeda J; Nakano Y; Kinoshita T; Inoue K
    J Immunol; 1984 Sep; 133(3):1464-70. PubMed ID: 6747294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Control of immune complexes by the classical pathway.
    Whaley K; Ahmed AE
    Behring Inst Mitt; 1989 Jul; (84):111-20. PubMed ID: 2529842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement-mediated inhibition of immune precipitation. I. Role of the classical and alternative pathways.
    Schifferli JA; Woo P; Peters DK
    Clin Exp Immunol; 1982 Mar; 47(3):555-62. PubMed ID: 6979442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of C3 deposition on solid-phase bound immune complexes by lactoferrin.
    Kievits F; Kijlstra A
    Immunology; 1985 Mar; 54(3):449-56. PubMed ID: 3844370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of C1, C1-inactivator and C4 in modulating immune precipitation.
    Schifferli JA; Steiger G; Schapira M
    Clin Exp Immunol; 1985 Jun; 60(3):605-12. PubMed ID: 4017288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative importance of C3b inactivator and beta 1H globulin in the modulation of the properdin amplification loop in systemic lupus erythematosus.
    Whaley K; Schur PH; Ruddy S
    Clin Exp Immunol; 1979 Jun; 36(3):408-14. PubMed ID: 114347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Formation of classical C3 convertase during the alternative pathway of human complement activation].
    Kozlov LV; Shibanova ED; Zinchenko AA
    Biokhimiia; 1987 Apr; 52(4):660-6. PubMed ID: 3647798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of rat complement by soluble and insoluble rat IgA immune complexes.
    Rits M; Hiemstra PS; Bazin H; Van Es LA; Vaerman JP; Daha MR
    Eur J Immunol; 1988 Dec; 18(12):1873-80. PubMed ID: 3220102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Requirements for beta1H globulin and C3b inactivator in the control of the alternative complement pathway in human serum.
    Whaley K; Thompson RA
    Immunology; 1978 Dec; 35(6):1045-9. PubMed ID: 83964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune complex modulation by plasma proteins. With special reference to the complement system and autoimmune diseases.
    Baatrup G
    Dan Med Bull; 1989 Oct; 36(5):443-63. PubMed ID: 2530063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. gp 58/68, a parasite component that contributes to the escape of the trypomastigote form of T. cruzi from damage by the human alternative complement pathway.
    Fischer E; Ouaissi MA; Velge P; Cornette J; Kazatchkine MD
    Immunology; 1988 Oct; 65(2):299-303. PubMed ID: 2973433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assembly of the membrane attack complex promotes decay of the alternative pathway C3 convertase on Neisseria gonorrhoeae.
    Densen P; McRill CM; Ross SC
    J Immunol; 1988 Dec; 141(11):3902-9. PubMed ID: 3141507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of classical pathway components during alternative pathway--modulated immune complex aggregation: the role of C1 INH.
    Gronski P; Bodenbender L; Kanzy EJ; Seiler FR
    Behring Inst Mitt; 1984 Nov; (76):29-41. PubMed ID: 6335396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The alternative complement pathway].
    Jouvin MH; Kazatchkine M
    Pathol Biol (Paris); 1983 Dec; 31(10):839-46. PubMed ID: 6230588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative pathway complement activation in rheumatoid arthritis.
    El-Ghobarey A; Whaley K
    J Rheumatol; 1980; 7(4):453-60. PubMed ID: 6158571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralization of influenza virus by normal human sera: mechanisms involving antibody and complement.
    Beebe DP; Schreiber RD; Cooper NR
    J Immunol; 1983 Mar; 130(3):1317-22. PubMed ID: 6822737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of alternative pathway and factor B haemolytic activities in patients with systemic lupus erythematosus: correlations with the alternative pathway regulatory proteins.
    Aguado MT; Perrin LH; Ramirez R; Miescher PA; Lambert PH
    Clin Exp Immunol; 1980 Dec; 42(3):495-505. PubMed ID: 6163579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of gangliosides on activation of the alternative pathway of human complement.
    Michalek MT; Bremer EG; Mold C
    J Immunol; 1988 Mar; 140(5):1581-7. PubMed ID: 3346542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.